BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ, Julie DOBROVOLNÁ, Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER and DeLisa FAIRWEATHER. Sex and age differences in sST2 in cardiovascular disease. Frontiers in Cardiovascular Medicine. Lausanne: Frontiers Media SA, 2023, vol. 9, January 2023, p. 1-19. ISSN 2297-055X. Available from: https://dx.doi.org/10.3389/fcvm.2022.1073814.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Sex and age differences in sST2 in cardiovascular disease
Authors BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ (203 Czech Republic, belonging to the institution), Julie DOBROVOLNÁ (203 Czech Republic, belonging to the institution), Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER and DeLisa FAIRWEATHER.
Edition Frontiers in Cardiovascular Medicine, Lausanne, Frontiers Media SA, 2023, 2297-055X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.600 in 2022
RIV identification code RIV/00216224:14110/23:00134703
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fcvm.2022.1073814
UT WoS 000923390600001
Keywords in English biomarkers; heart failure; myocardial infarct; coronary artery disease; cardiomyopathy; congestive heart failure
Tags 14110115, 14110518
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 08:48.
Abstract
AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs). MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293), coronary artery disease (CAD) (n = 239), myocardial infarct (MI) (n = 159), and congestive heart failure (CHF) (n = 286) and compared them to controls that did not have CVDs (n = 234). ResultsMyocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, p = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis (p <= 0.0001), cardiomyopathy (p = 0.0009), CAD (p = 0.03), MI (p = 0.034), and CHF (p < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females (p = 0.002) and males (p <= 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis p = 0.0035; cardiomyopathy p = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men (p = 0.0004) or women under 50 years of age (p = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women (p = 0.012 and p = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range (p = 0.02). ConclusionWe found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.
Links
NU22-02-00418, research and development projectName: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 13/7/2024 17:30